These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Distribution of RET Mutations and Evaluation of Treatment Approaches in Hereditary Medullary Thyroid Carcinoma in Turkey. Aydoğan Bİ; Yüksel B; Tuna MM; Navdar Başaran M; Akkurt Kocaeli A; Ertörer ME; Aydın K; Güldiken S; Şimşek Y; Cihan Karaca Z; Yılmaz M; Aktürk M; Anaforoğlu İ; Kebapçı N; Duran C; Taşlıpınar A; Kulaksızoğlu M; Gürsoy A; Dağdelen S; Erdoğan MF J Clin Res Pediatr Endocrinol; 2016 Mar; 8(1):13-20. PubMed ID: 26758973 [TBL] [Abstract][Full Text] [Related]
3. [The treatment of medullary thyroid cancer]. Fujita T; Fujimori M Gan To Kagaku Ryoho; 2009 Oct; 36(10):1627-31. PubMed ID: 19838021 [TBL] [Abstract][Full Text] [Related]
4. The RET mutation E768D confers a late-onset familial medullary thyroid carcinoma -- only phenotype with incomplete penetrance: implications for screening and management of carrier status. Dabir T; Hunter SJ; Russell CF; McCall D; Morrison PJ Fam Cancer; 2006; 5(2):201-4. PubMed ID: 16736292 [TBL] [Abstract][Full Text] [Related]
5. Twenty years of lesson learning: how does the RET genetic screening test impact the clinical management of medullary thyroid cancer? Romei C; Tacito A; Molinaro E; Agate L; Bottici V; Viola D; Matrone A; Biagini A; Casella F; Ciampi R; Materazzi G; Miccoli P; Torregrossa L; Ugolini C; Basolo F; Vitti P; Elisei R Clin Endocrinol (Oxf); 2015 Jun; 82(6):892-9. PubMed ID: 25440022 [TBL] [Abstract][Full Text] [Related]
7. Current understanding and management of medullary thyroid cancer. Roy M; Chen H; Sippel RS Oncologist; 2013; 18(10):1093-100. PubMed ID: 24037980 [TBL] [Abstract][Full Text] [Related]
8. All in the family? Analyzing the impact of family history in addition to genotype on medullary thyroid carcinoma aggressiveness in MEN2A patients. Long KL; Etzel C; Rich T; Hyde S; Perrier ND; Graham PH; Lee JE; Hu MI; Cote GJ; Gagel R; Grubbs EG Fam Cancer; 2017 Apr; 16(2):283-289. PubMed ID: 27864651 [TBL] [Abstract][Full Text] [Related]
9. Medullary Thyroid Carcinoma Associated with Germline RET Xu JY; Grubbs EG; Waguespack SG; Jimenez C; Gagel RF; Sosa JA; Sellin RV; Dadu R; Hu MI; Trotter CS; Jackson M; Rich TA; Hyde SM; Sherman SI; Cote GJ Thyroid; 2016 Dec; 26(12):1744-1751. PubMed ID: 27673361 [TBL] [Abstract][Full Text] [Related]
10. Management of medullary thyroid carcinoma. Jiménez C; Hu MI; Gagel RF Endocrinol Metab Clin North Am; 2008 Jun; 37(2):481-96, x-xi. PubMed ID: 18502338 [TBL] [Abstract][Full Text] [Related]
11. New presentation of familial medullary thyroid carcinoma in 87-year-old patient with high-risk RET proto-oncogene codon 620 mutation. Jaggard MK; MacRae C; Ifeacho S; Robinson S; Tolley NS J Laryngol Otol; 2009 Jul; 123(7):796-800. PubMed ID: 18771606 [TBL] [Abstract][Full Text] [Related]
12. Genomics and Epigenomics of Medullary Thyroid Carcinoma: From Sporadic Disease to Familial Manifestations. Barletta JA; Nosé V; Sadow PM Endocr Pathol; 2021 Mar; 32(1):35-43. PubMed ID: 33492588 [TBL] [Abstract][Full Text] [Related]
13. Hereditary medullary thyroid carcinoma: the management dilemma. Zhou P; Liu J; Cheng SW; Wang B; Yang R; Peng L Fam Cancer; 2012 Jun; 11(2):157-65. PubMed ID: 22183190 [TBL] [Abstract][Full Text] [Related]
14. Familial medullary carcinoma prevention, risk evaluation, and RET in children of families with MEN2. Moore SW; Appfelstaedt J; Zaahl MG J Pediatr Surg; 2007 Feb; 42(2):326-32. PubMed ID: 17270543 [TBL] [Abstract][Full Text] [Related]
15. [Familial medullary thyroid carcinoma: case report and literature review.]. Barletta Carrillo CF; Poterico Rojas JA; Barrionuevo Cornejo C; Casavilca Zambrano S; Pinedo Cárdenas A; Quispe Santibañez I; Castro Mujica MDC Rev Fac Cien Med Univ Nac Cordoba; 2018 Dec; 75(4):303-309. PubMed ID: 30734711 [TBL] [Abstract][Full Text] [Related]
16. Clinical case seminar: in vivo and in vitro characterization of a novel germline RET mutation associated with low-penetrant nonaggressive familial medullary thyroid carcinoma. D'Aloiso L; Carlomagno F; Bisceglia M; Anaganti S; Ferretti E; Verrienti A; Arturi F; Scarpelli D; Russo D; Santoro M; Filetti S J Clin Endocrinol Metab; 2006 Mar; 91(3):754-9. PubMed ID: 16384843 [TBL] [Abstract][Full Text] [Related]
17. Hereditary medullary thyroid carcinoma: how molecular genetics made multiple endocrine neoplasia type 2 a paediatric disease. Szinnai G; Sarnacki S; Polak M Endocr Dev; 2007; 10():173-187. PubMed ID: 17684396 [TBL] [Abstract][Full Text] [Related]
18. Molecular mechanisms of medullary thyroid carcinoma: current approaches in diagnosis and treatment. Boikos SA; Stratakis CA Histol Histopathol; 2008 Jan; 23(1):109-16. PubMed ID: 17952863 [TBL] [Abstract][Full Text] [Related]
19. Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update. Wells SA; Pacini F; Robinson BG; Santoro M J Clin Endocrinol Metab; 2013 Aug; 98(8):3149-64. PubMed ID: 23744408 [TBL] [Abstract][Full Text] [Related]
20. Modifying impact of Kaczmarek-Ryś M; Ziemnicka K; Pławski A; Budny B; Michalak M; Hryhorowicz S; Hoppe-Gołębiewska J; Boruń P; Gołąb M; Czetwertyńska M; Sromek M; Szalata M; Ruchała M; Słomski R Endocr Relat Cancer; 2018 Apr; 25(4):421-436. PubMed ID: 29386230 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]